The popular Shin Megami Tensei video game series is getting a physical board game. A Japanese company called Icrea is behind the effort and is launching a Kickstarter on November 12 to raise funds for the project.

SHIN MEGAMI TENSEI THE BOARD GAME (the company asked us to use all caps) is a “full-scale board game project” complete with 72 “high quality and detailed demon figures.” Collecting demons and adding them to your party is a major part of the game, so these figurines should help with immersion. It’ll also help with getting random demon figurines lost in the couch.

Icrea/Atlus

There’s a board with various locations from the franchise and plenty of series-specific cards to rifle through. The company says a game should take anywhere from three to four hours. The title has already generated a fair amount of excitement at both Gen Con and the most recent Tokyo Game Show.

We don’t know exactly when this will be available for purchase. You know how Kickstarter timelines work. There are going to be a bunch of stretch goals, however, should the company reach the initial financial threshold. It’s a Shin Megami Tensei board game with dozens of cool-looking demon figurines. It shouldn’t have any trouble finding financial backers.

For the uninitiated, Shin Megami Tensei first came out in 1992 for the Super Famicom in Japan. There have been plenty of sequels throughout the years. Shin Megami Tensei V came out back in 2021, but has since received a full-featured refresh called Shin Megami Tensei V: Vengeance.

The Persona series is also a spinoff of the franchise. This leads to a very serious question. Persona board game when? I want to wander around a fake high school and eat ramen with a motley crew of characters.

This article originally appeared on Engadget at https://www.engadget.com/gaming/this-shin-megami-tensei-board-game-features-72-intricate-demon-figurines-163242838.html?src=rss

Madden NFL has been around for almost 40 years (really) so it’s high time the gaming franchise got the documentary treatment. Prime Video has got you covered. The platform just announced that It’s in the Game: Madden NFL will stream on November 26, which is just ahead of Thanksgiving.

The four-part docuseries will explore “one of the biggest video games of all time” that “became a worldwide phenomenon, spanning generations.” The show will explore Madden’s “archaic 8-bit origins to its success as an annual must have.” Prime Video says EA Sports has given it access to the vaults, so there should be plenty of new footage for diehard fans.

As the story goes, EA founder Trip Hawkins approached commentator John Madden back in 1984 for his endorsement and expertise, but the game took four long years of development before coming out in 1988. This extended development time was allegedly due to Madden himself, who demanded a realistic football experience. I’m sure the documentary will get into all of that.

Formerly known as John Madden Football, the franchise became an annual event in 1990 and changed its name to Madden NFL in 1993. These games have sold over 130 million copies worldwide since 1988. The latest iteration, Madden NFL 25, released back in August to fairly middling reviews.

This article originally appeared on Engadget at https://www.engadget.com/entertainment/tv-movies/a-tv-show-about-ea-sports-madden-games-hits-prime-video-on-november-26-194833398.html?src=rss

Fujifilm is developing a medium-format, 102-megapixel cinema camera, the company said in a surprise announcement. Due next year, the GFX Eterna will carry a boxy, modular design reminiscent of Sony's FX6 or the new Blackmagic Pyxis and will likely be launched with a top handle, electronic viewfinder and other optional accessories.

The new camera will have a medium format GFX 102-megapixel (MP) CMOS II HS sensor, the same one used on the GFX100 II. That sensor is 43.8mm x 32.9 mm in size, or 1.7 times larger than the full-frame sensor found on the aforementioned FX or Pyxis. That will be one of the largest cinema camera sensors available, even bigger than RED's V-Raptor XL sensor.

The benefits will be extra dynamic range, potentially high resolution and a very shallow depth of field that should allow for cinematic shots when paired with the right lens. That does bring up the fact that Fujifilm currently has no GFX glass designed specifically for film production. However, the company said it's developing a 32-90mm power zoom lens (24-70mm full-frame equivalent) and will have a mount adapter for GFX to PL lenses, which are widely used in cinema. 

One other concern might be rolling shutter distortion. RED's V-Raptor XL uses a global shutter that has zero distortion, but the sensor Fujifilm will employ has a fair bit of it . In addition, the GFX100 II captures 8K with a 1.53x crop, negating many of the benefits of a medium format sensor — so, hopefully Fujifilm will resolve those issues with its cinema camera. 

Fujifilm will show off the GFX Eterna starting tomorrow at the InterBEE 2024 media exhibition in Chiba City, Japan. It's set to be released sometime in 2025, with an exact date and pricing yet to be announced.

This article originally appeared on Engadget at https://www.engadget.com/cameras/fujifilm-is-developing-a-102mp-medium-format-cinema-camera-130027537.html?src=rss

This year may not go down as one of the best years in gaming like 2023 did, but that doesn’t mean there weren’t a lot of great new releases. Between titles like Astro Bot and Final Fantasy 7 Rebirth, there were plenty of games to keep even the most dedicated of gamers busy in 2024. And if you’re shopping for one, especially as a non-gamer, it can be tricky to navigate what’s worth buying. Don’t worry, Engadget is here to help. We guarantee this gift guide will help you find something for your game-loving friend or loved one.

Check out the rest of our gift ideas here.

This article originally appeared on Engadget at https://www.engadget.com/gaming/best-gaming-gifts-for-gamers-150008483.html?src=rss

Los Angeles CA (SPX) Nov 05, 2024
Imagining a vast ice sheet sprawling over Canada and extending down into what is now the northern United States, reaching as far south as Pennsylvania, Ohio, Indiana, Michigan, and Wisconsin, helps us grasp the scope of ancient glacial coverage between 19,000 and 26,000 years ago. Yet, while picturing this immense ice mass is fascinating, the present-day implications of its retreat - parti

Ontario Premier Doug Ford appears to be dipping his toe into new territory — talking about removing Mexico from the North American trade agreement.

Gros succès en France, le drame biographique est présenté samedi au Festival Cinemania.

James Van Der Beek s’est ouvert sur son combat contre le cancer.

IF DOMINATING the streaming industry wasn’t enough, Netflix has just launched its very first video game, which features characters from its own shows.

Jesse James has a legendary moniker, and now the martial arts black belt is set to make his own name known on the world stage, representing Australia.

The recent amendments brought by the Union Ministry of Ayush to the Drugs and Cosmetics Rules, 1945 are significant, as they introduce new regulatory requirements for the manufacturing and sale of traditional

An inter─ministerial committee formed by the Union health ministry has recommended amendments to the Food Safety and Standards Act, 2006 and regulations on nutraceuticals and health supplements, to shift regulation of

WITTMANN BATTENFELD will present the latest solutions for time and cost optimisation in the production of parts with nano structures at Compamed, booth No. F03-1 in hall 8b.

Accumold, with over 40 years of experience in micromoulding technology, is set to participate at Compamed, taking place in Düsseldorf, Germany, from 11-14 November. The company will highlight its small and complex parts for medical device OEMs.

Syensqo, previously part of Solvay Group and a global provider of advanced performance materials and chemical solutions, is making its debut at Compamed 2024.

Trelleborg Medical Solutions showcases its comprehensive polymer-based solutions and capabilities for the medical technology and biopharmaceutical industries at Compamed 2024 in Dusseldorf from November 11 to 14, at stand F02 in hall 8A.

The U.S. Food and Drug Administration posted a video:

Los medicamentos de receta pasan por muchos pasos y fases importantes antes de que los aprobemos. Las investigaciones, los datos y la evidencia deben demostrar que el medicamento es seguro y eficaz para el uso previsto. Aprenda más sobre el proceso de aprobación de la FDA de principio a fin.

Para obtener más información sobre el papel de la FDA en la regulación y la aprobación de medicamentos, visite nuestro sitio web en www.fda.gov/drugs/information-consumers-and-patients-drug...

Vea esta serie de tres partes: www.youtube.com/playlist?list=PL0AE2C851E6968546

The U.S. Food and Drug Administration posted a video:

Quizás sepa que la FDA es responsable de aprobar los medicamentos nuevos, como medicamentos de receta, genéricos, biosimilares y de venta libre, y de garantizar que esos medicamentos sean seguros, de alta calidad y funcionen como se supone que deben hacerlo. Pero nuestro trabajo no termina ahí. Continuamos monitoreando la seguridad y calidad de los medicamentos aprobados en los años venideros. Aprenda más sobre nuestro papel en la regulación de estos medicamentos.

Para obtener más información sobre el papel de la FDA en la regulación y la aprobación de medicamentos, visite nuestro sitio web en www.fda.gov/drugs/information-consumers-and-patients-drug...

Vea esta serie de tres partes: www.youtube.com/playlist?list=PL0AE2C851E6968546

The U.S. Food and Drug Administration posted a video:

¿Qué son los biosimilares? Los biosimilares son un tipo de medicamento que se usa para tratar una variedad de afecciones, como enfermedades crónicas de la piel y los intestinos, artritis, diabetes, afecciones renales, degeneración macular y algunos tipos de cáncer. Un biosimilar es un tipo de medicamento biológico. La mayoría de los medicamentos biológicos se elaboran usando fuentes vivas, como células animales, bacterias o levaduras. Debido a que en su mayoría provienen de fuentes vivas, todos los tipos de productos biológicos tienen diferencias menores que ocurren naturalmente entre los lotes de producción. Así como los medicamentos de marca tienen versiones genéricas, los biológicos originales pueden tener biosimilares. La cuidadosa revisión de datos, estudios y pruebas por parte de la FDA ayuda a garantizar que los productos biosimilares brinden los mismos beneficios de tratamiento que el producto biológico original aprobado por la FDA. Los biosimilares pueden brindarle más acceso a tratamientos importantes y también pueden ahorrarle dinero, dependiendo de su cobertura de seguro. Se han aprobado muchos biosimilares diferentes y se esperan aún más. Para obtener más información, visite www.fda.gov/biosimilars

The U.S. Food and Drug Administration posted a video:

La FDA monitorea continuamente datos en tiempo real de pacientes, fabricantes de medicamentos y profesionales de la salud, incluyendo informes de reacciones adversas a los medicamentos de receta. Según estos datos, podemos actualizar las etiquetas de los medicamentos o, en casos excepcionales, solicitar la retirada del mercado. Aprenda más sobre el proceso de la FDA para el monitoreo continuo de los medicamentos aprobados.

Para obtener más información sobre el papel de la FDA en la regulación y la aprobación de medicamentos, visite nuestro sitio web en www.fda.gov/drugs/information-consumers-and-patients-drug...

Vea esta serie de tres partes: www.youtube.com/playlist?list=PL0AE2C851E6968546

The U.S. Food and Drug Administration posted a video:

Quizás sepa que la FDA es responsable de aprobar los medicamentos nuevos, como medicamentos de receta, genéricos, biosimilares y de venta libre, y de garantizar que esos medicamentos sean seguros, de alta calidad y funcionen como se supone que deben hacerlo. Pero nuestro trabajo no termina ahí. Continuamos monitoreando la seguridad y calidad de los medicamentos aprobados en los años venideros. Aprenda más sobre nuestro papel en la regulación de estos medicamentos.

Para obtener más información sobre el papel de la FDA en la regulación y la aprobación de medicamentos, visite nuestro sitio web en www.fda.gov/drugs/information-consumers-and-patients-drug...

The U.S. Food and Drug Administration posted a video:

Los medicamentos de receta pasan por muchos pasos y fases importantes antes de que los aprobemos. Las investigaciones, los datos y la evidencia deben demostrar que el medicamento es seguro y eficaz para el uso previsto. Aprenda más sobre el proceso de aprobación de la FDA de principio a fin.

Para obtener más información sobre el papel de la FDA en la regulación y la aprobación de medicamentos, visite nuestro sitio web en www.fda.gov/drugs/information-consumers-and-patients-drug...

The U.S. Food and Drug Administration posted a video:

La FDA monitorea continuamente datos en tiempo real de pacientes, fabricantes de medicamentos y profesionales de la salud, incluyendo informes de reacciones adversas a los medicamentos de receta. Según estos datos, podemos actualizar las etiquetas de los medicamentos o, en casos excepcionales, solicitar la retirada del mercado. Aprenda más sobre el proceso de la FDA para el monitoreo continuo de los medicamentos aprobados.

Para obtener más información sobre el papel de la FDA en la regulación y la aprobación de medicamentos, visite nuestro sitio web en www.fda.gov/drugs/information-consumers-and-patients-drug...

The FDA doesn’t care about the First Amendment rights of the companies it regulates. It cares even less about the “free speech” rights of those companies’ sales and marketing representatives. And why should the agency care? One of FDA’s primary missions is to protect the public health and safety of the American people from illegal, adulterated and misbranded products. Doing so involves restraining food, drug, device and cosmetics companies from committing fraudulent and deceptive acts that are not protected by companies’ commercial free speech rights. Nonetheless, FDA Matters envisions opportunities for FDA and industry to broaden permissible product communications. The key is understanding history, not constitutional law.

Two former board chairs of the Coalition for Healthcare Communication (CHC) were named as the Medical Advertising Hall of Fame (MAHF) 2025 inductees – Sharon Callahan, former Chief Client Officer at Omnicom Health Group (OHG), and Nick Colucci, former Chairman and CEO of Publicis Health/COO of Publicis Groupe North America. The inductees will be honored […]

An AllTrials report for the House of Commons Science and Technology Select Committee this week has found that 33 NHS trust sponsors and six UK universities are reporting none of their clinical trial results, while others have gone from 0% to 100% following an announcement from the Select Committee in January that universities and NHS […]

[Fair Warning: I have generally tried to keep this blog separate from my corporate existence, but am making an exception for two quick posts about the upcoming DIA 2013 Annual Meeting.]

Improving Enrollment in Pediatric Clinical Trials

Logistically, ethically, and emotionally, involving children in medical research is greatly different from the same research in adults. Some of the toughest clinical trials I've worked on, across a number of therapeutic areas, have been pediatric ones. They challenge you to come up with different approaches to introducing and explaining clinical research – approaches that have to work for doctors, kids, and parents simultaneously.

On Thursday June 27, Don Sickler, one of my team members, will be chairing a session titled “Parents as Partners: Engaging Caregivers for Pediatric Trials”. It should be a good session.

Joining Don are 2 people I've had the pleasure of working with in the past. Both of them combine strong knowledge of clinical research with a massive amount of positive energy and enthusiasm (no doubt a big part of what makes them successful).

However, they also differ in one key aspect: what they work on. One of them – Tristen Moors from Hyperion Therapeutics - works on an ultra-rare condition, Urea Cycle Disorder, a disease affecting only a few hundred children every year. On the other hand, Dr. Ann Edmunds is an ENT working in a thriving private practice. I met her because she was consistently the top enroller in a number of trials relating to tympanostomy tube insertion. Surgery to place “t-tubes” is one of the most common and routine outpatients surgeries there is, with an estimated half million kids getting tubes each year.

Each presents a special challenge: for rare conditions, how do you even find enough patients? For routine procedures, how do you convince parents to complicate their (and their children’s) lives by signing up for a multi-visit, multi-procedure trial?

Ann and Tristen have spent a lot of time tackling these issues, and should have some great advice to give.

For more information on the session, here’s Don’s posting on our news blog.

Are we looking at our enrollment data in the right way?

Session Details:

June 25, 1:45PM - 3:15PM

• Session Number: 241
• Room Number: 205B

1. Enrollment Analytics: Moving Beyond the Funnel
Paul Ivsin
VP, Consulting Director
CAHG Clinical Trials

2. Use of Analytics for Operational Planning
Diana Chung, MSc
Associate Director, Clinical Operations
Gilead
3. Using Enrollment Data to Communicate Effectively with Sites
Gretchen Goller, MA
Senior Director, Patient Access and Retention Services
PRA

Dalam dunia perjudian online yang terus berkembang, pencarian para pemain untuk menemukan peluang terbaik dalam meraih kemenangan mengarah pada fenomena populer: kumpulan game slot gacor dengan persentase RTP tertinggi hari…

The post Kumpulan Game Slot Gacor Dengan Persentase RTP Tertinggi Hari Ini appeared first on Biosimilarnews.

Habanero tidak hanya menyajikan game slot biasa, melainkan sebuah petualangan menang tanpa batas. Dengan tema-tema yang beragam, mulai dari petualangan antariksa hingga ke dunia mitologi, setiap game Habanero memiliki keunikan…

The post Game Slot Gacor Gampang Menang Habanero appeared first on Biosimilarnews.

Did that rock move, or is it a squirrel crossing the road? Tracking objects that look a lot like their surroundings is a big problem for many autonomous vision systems. AI algorithms can solve this camouflage problem, but they take time and computing power. A new camera designed by researchers in South Korea provides a faster solution. The camera takes inspiration from the eyes of a cat, using two modifications that let it distinguish objects from their background, even at night.

“In the future … a variety of intelligent robots will require the development of vision systems that are best suited for their specific visual tasks,” says Young Min Song, a professor of electrical engineering and computer science at Gwangju Institute of Science and Technology and one of the camera’s designers. Song’s recent research has been focused on using the “perfectly adapted” eyes of animals to enhance camera hardware, allowing for specialized cameras for different jobs. For example, fish eyes have wider fields of view as a consequence of their curved retinas. Cats may be common and easy to overlook, he says, but their eyes actually offer a lot of inspiration.

This particular camera copied two adaptations from cats’ eyes: their vertical pupils and a reflective structure behind their retinas. Combined, these allowed the camera to be 10 percent more accurate at distinguishing camouflaged objects from their backgrounds and 52 percent more efficient at absorbing incoming light.

Using a vertical pupil to narrow focus

While conventional cameras can clearly see the foreground and background of an image, the slitted pupils of a cat focus directly on a target, preventing it from blending in with its surroundings. Kim et al./Science Advances

In conventional camera systems, when there is adequate light, the aperture—the camera’s version of a pupil—is small and circular. This structure allows for a large depth of field (the distance between the closest and farthest objects in focus), clearly seeing both the foreground and the background. By contrast, cat eyes narrow to a vertical pupil during the day. This shifts the focus to a target, distinguishing it more clearly from the background.

The researchers 3D printed a vertical slit to use as an aperture for their camera. They tested the vertical slit using seven computer vision algorithms designed to track moving objects. The vertical slit increased contrast between a target object and its background, even if they were visually similar. It beat the conventional camera on five of the seven tests. For the two tests it performed worse than the conventional camera, the accuracies of the two cameras were within 10 percent of each other.

Using a reflector to gather additional light

Cats can see more clearly at night than conventional cameras due to reflectors in their eyes that bring extra light to their retinas.Kim et al./Science Advances

Cat eyes have an in-built reflector, called a tapetum lucidum, which sits behind the retina. It reflects light that passes through the retina back at it, so it can process both the incoming light and reflected light, giving felines superior night vision. You can see this biological adaptation yourself by looking at a cat’s eyes at night: they will glow.

The researchers created an artificial version of this biological structure by placing a silver reflector under each photodiode in the camera. Photodiodes without a reflector generated current when more than 1.39 watts per square meter of light fell on them, while photodiodes with a reflector activated with 0.007 W/m² of light. That means the photodiode could generate an image with about 1/200th the light.

Each photodiode was placed above a reflector and joined by metal electrodes to create a curved image sensor.Kim et al./Science Advances

To decrease visual aberrations (imperfections in the way the lens of the camera focuses light), Song and his team opted to create a curved image sensor, like the back of the human eye. In such a setup, a standard image sensor chip won’t work, because it’s rigid and flat. Instead it often relies on many individual photodiodes arranged on a curved substrate. A common problem with such curved sensors is that they require ultrathin silicon photodiodes, which inherently absorb less light than a standard imager’s pixels. But reflectors behind each photodiode in the artificial cat’s eye compensated for this, enabling the researchers to create a curved imager without sacrificing light absorption.

Together, vertical slits and reflectors led to a camera that could see more clearly in the dark and isn’t fooled by camouflage. “Applying these two characteristics to autonomous vehicles or intelligent robots could naturally improve their ability to see objects more clearly at night and to identify specific targets more accurately,” says Song. He foresees this camera being used for self-driving cars or drones in complex urban environments.

Song’s lab is continuing to work on using biological solutions to solve artificial vision problems. Currently, they are developing devices that mimic how brains process images, hoping to one day combine them with their biologically-inspired cameras. The goal, says Song, is to “mimic the neural systems of nature.”

Song and his colleague’s work was published this week in the journal Science Advances.

This article appears in the November 2024 print issue.

Over the past 20 years, technological advances have enabled inventors to go from strength to strength. And yet, according to the legendary inventor Dean Kamen, innovation has stalled. Kamen made a name for himself with inventions including the first portable insulin pump for diabetics, an advanced wheelchair that can climb steps, and the Segway mobility device. Here, he talks about his plan for enabling innovators.

How has inventing changed since you started in the 1990s?

Dean Kamen: Kids all over the world can now be inventing in the world of synthetic biology the way we played with Tinkertoys and Erector Sets and Lego. I used to put pins and smelly formaldehyde in frogs in high school. Today in high school, kids will do experiments that would have won you the Nobel Prize in Medicine 40 years ago. But none of those kids are likely in any short time to be on the market with a pharmaceutical that will have global impact. Today, while invention is getting easier and easier, I think there are some aspects of innovation that have gotten much more difficult.

Can you explain the difference?

Kamen: Most people think those two words mean the same thing. Invention is coming up with an idea or a thing or a process that has never been done that way before. [Thanks to] more access to technology and 3D printers and simulation programs and virtual ways to make things, the threshold to be able to create something new and different has dramatically lowered.

Historically, inventions were only the starting point to get to innovation. And I’ll define an innovation as something that reached a scale where it impacted a piece of the world, or transformed it: the wheel, steam, electricity, Internet. Getting an invention to the scale it needs to be to become an innovation has gotten easier—if it’s software. But if it’s sophisticated technology that requires mechanical or physical structure in a very competitive world? It’s getting harder and harder to do due to competition, due to global regulatory environments.

[For example,] in proteomics [the study of proteins] and genomics and biomedical engineering, the invention part is, believe it or not, getting a little easier because we know so much, because there are development platforms now to do it. But getting a biotech product cleared by the Food and Drug Administration is getting more expensive and time consuming, and the risks involved are making the investment community much more likely to invest in the next version of Angry Birds than curing cancer.

A lot of ink has been spilled about how AI is changing inventing. Why hasn’t that helped?

Kamen: AI is an incredibly valuable tool. As long as the value you’re looking for is to be able to collect massive amounts of data and being able to process that data effectively. That’s very different than what a lot of people believe, which is that AI is inventing and creating from whole cloth new and different ideas.

How are you using AI to help with innovation?

Kamen: Every medical school has incredibly brilliant professors and grad students with petri dishes. “Look, I can make nephrons. We can grow people a new kidney. They won’t need dialysis.” But they only have petri dishes full of the stuff. And the scale they need is hundreds and hundreds of liters.

I started a not-for-profit called ARMI—the Advanced Regenerative Manufacturing Institute—to help make it practical to manufacture human cells, tissues, and organs. We are using artificial intelligence to speed up our development processes and eliminate going down frustratingly long and expensive [dead-end] paths. We figure out how to bring tissue manufacturing to scale. We build the bioreactors, sensor technologies, robotics, and controls. We’re going to put them together and create an industry that can manufacture hundreds of thousands of replacement kidneys, livers, pancreases, lungs, blood, bone, you name it.

So ARMI’s purpose is to help would-be innovators?

Kamen: We are not going to make a product. We’re not even going to make a whole company. We’re going to create baseline core technologies that will enable all sorts of products and companies to emerge to create an entire new industry. It will be an innovation in health care that will lower costs because cures are much cheaper than chronic treatments. We have to break down the barriers so that these fantastic inventions can become global innovations.

This article appears in the November 2024 print issue as “The Inventor’s Inventor.”

WASHINGTON — US President-elect Donald Trump said on Nov 12 that Elon Musk and former Republican presidential hopeful Vivek Ramaswamy will lead the newly created Department of Government Efficiency. Musk and Ramaswamy "will pave the way for my Administration to dismantle Government Bureaucracy, slash excess regulations, cut wasteful expenditures, and restructure Federal Agencies", Trump said in a statement. Trump said their work would conclude by July 4, 2026, adding that a smaller and more efficient government would be a "gift" to the country on the 250th anniversary of the signing of the Declaration of Independence. Businessman and former Republican presidential candidate Vivek Ramaswamy attends Donald Trump's campaign event sponsored by conservative group Turning Point Action, in Las Vegas, Nevada, US, Oct 24, 2024. PHOTO: Reuters file The appointments reward two Trump supporters from the private sector.

In July 2024, internet personality Bobby Saputra posted a video of himself living it up at what appeared to be the star-studded, ultra-lavish wedding of Radhika Merchant and Anant Ambani, the youngest child of Indian billionaire and Asia's richest man, Mukesh Ambani. The video featured clips of Saputra dancing, feasting and soaking up the "completely crazy" celebrations. He gushes in the voiceover: "It was like watching a Bollywood production." The video quickly went viral, racking up 6.6 million views on Instagram, 5.1 million on TikTok, and another 2.2 million on YouTube. Thousands left comments, including some celebrities who claimed they spotted him there. Except… he never set foot in the party. As it turns out, he had pieced together clips from a wedding he attended a few months prior — complete with him in full Indian attire, dancing with friends — and spliced in shots from the Ambani wedding that he found online. The result? Social media magic.

Aug 1, 2023

Using the private journals of commission secretaries Henry Marie Brackenridge and Dr. William Baldwin, as well as Captain Sinclair, this chapter will explore the establishment of American naval identity through its diplomatic experiences in South America. It will also exhibit the role of the U.S. Navy in a proto framework of the Monroe Doctrine.

Mar 12, 2024

After a century of rebellion, South America experienced a rapid decline in revolts in the early 1900s. Historical narratives and an analysis of a comprehensive new dataset show that the decrease stemmed in large part from the expansion and professionalization of the region’s militaries, which were driven by an export boom and the threat of interstate conflict. 

Oct 21, 2022

Colin L. Powell was a great American. A brilliant soldier, statesman and patriot, he devoted his life to public service, and he cherished the United States, his family and his many friends. While acknowledging America’s challenges, he drew inspiration from its noble purpose and promise. “America remains the last best hope of Earth,” he said in his 1994 Howard University commencement address “You are its inheritors, and its future is today placed in your hands.” The trajectory of his life—from humble beginnings as a Jamaican immigrant’s son growing up in the Bronx to the highest levels of government—is a true American dream. 

Nov 18, 2022

Former Colombian President Iván Duque discussed Latin America’s resurgent left wing and advocated for environmental action at the Harvard Kennedy School on Thursday afternoon.

Apr 10, 2023

The following is an event write-up about the recent Future of Diplomacy Project (FDP) seminar on “The Geopolitics of Latin America amid the War in Ukraine and China-U.S. Tensions” moderated by Negah Angha, Fellow at the Institute of Politics, on March 29, 2023.

May 23, 2024

MEI Fellow Yuree Noh assesses public opinion in Kuwait following the suspension of its parliament.

Mar 13, 2024

Social media’s unregulated evolution over the past decade holds a lot of lessons that apply directly to AI companies and technologies.

Jul 23, 2024

In the lead up to the October 2021 federal elections, the streets of Baghdad were lined with posters of female candidates. Some were familiar faces with clear political baggage and history, like Sara Iyad Allawi, the daughter of Iraq’s former prime minister. Others were former members of parliament from entrenched political parties. What drew the most excitement from observers, however, were the campaigns of civil activists who had participated in the October protest movement. Locally known as the “Tishreen Movement”, the October protest movement was the largest sustained protest movement in post-2003 Iraq’s history, which took place between October 2019 and February 2020 and involved the participation of hundreds of thousands across multiple cities. The protest movement succeeded in pushing for a new electoral law and in holding early elections, though the elections were only six months ahead of the traditional schedule by the time they were organized. These women represented a new type of female candidate, one without ties to the entrenched elite and who represented. Iraq’s youthful society. Their participation, like the protest movement itself, heralded to many a new era of Iraqi politics, one where younger women were confident enough to run for office and who relied on grassroots campaigning and social media.

Apr 17, 2024

Joseph Nye argues that episodes of "declinism" say more about popular psychology than geo-political analysis, but they also show how the idea of decline touches a raw nerve in American politics. China is not an existential threat to the United States unless U.S. leaders make it one by blundering into a major war.

Jul 11, 2024

Stephen Walt writes that doubts about Biden’s ability to do the job over the next six months must be balanced against the qualities that Trump exhibited when he oversaw U.S. foreign policy. Insider accounts of Trump’s first term portray him as erratic, mercurial, uninterested in details, and incapable of giving most foreign-policy problems sustained attention.

May 23, 2024

Framing climate policy actions to be acceptable by various stakeholders in cities poses a critical task for urban governance. This paper draws on the literature on climate change discourse to analyze the content of framing and its reasoning in the two municipalities located in the Arctic: Murmansk, Russia, and Tromsø, Norway.

Nov 16, 2023

Joseph Nye writes that Washington's strategy towards Beijing should be to avoid either a hot or cold war, co-operate when possible and marshal its assets to shape China's external behaviour. This can be done through deterrence and a strengthening of both alliances and international institutions.

Jan 24, 2024

In this Q&A, Joseph S. Nye talks about his advice for the interim and future president of Harvard in the wake of Claudine Gay's resignation, which countries should be highest on our radar to prevent the threat of nuclear war, what role the U.S. should play in the Russia-Ukraine war, the significance of U.S. alliances in the Middle East, and more.

Apr 15, 2024

Stephen Walt argues that the tragic irony is that the individuals and organizations in the United States that have been the most ardent in shielding Israel from criticism and pushing one administration after another to back Israel, no matter what it does, have in fact done enormous damage to the country that they were trying to help.

May 6, 2024

Stephen Walt advises protesters that people who haven't made up their minds yet are usually attracted by facts, logic, reason, and evidence. In his experience, they are turned off by anger, rudeness, intolerance, and especially by anyone who interferes with their own desire to learn more.